Ana Calizo

Ana Calizo

Auto-generated profile, based on publicly available information

Ana Calizo

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are lethal, Ras-driven sarcomas that lack effective therapies. We investigated effects of targeting cyclin-dependent kinases 4 and 6 (CDK4/6), MEK, and/or programmed death-ligand 1 (PD-L1) in preclinical MPNST models. Experimental Design: Patient-matched MPNSTs and precursor lesions were examined by FISH, RNA sequencing, IHC, and Connectivity-Map analyses. Antitumor activity of CDK4/6 and MEK inhibitors was measured in MPNST cell lines, patient-derived xenografts (PDX), and de novo mouse MPNSTs, with the latter used to determine anti–PD-L1 response. Results: Patient tumor analyses identified CDK4/6 and MEK as actionable targets for MPNST therapy. Low-dose combinations of CDK4/6 and MEK inhibitors synergistically reactivated the retinoblastoma (RB1) tumor suppressor, induced cell death, and decreased clonogenic survival of MPNST cells. In immune-deficient mice, dual CDK4/6-MEK inhibition slowed tumor growth in 4 of 5 MPNST PDXs. In immunocompetent mice, combination therapy of de novo MPNSTs caused tumor regression, delayed resistant tumor outgrowth, and improved survival relative to monotherapies. Drug-sensitive tumors that regressed contained plasma cells and increased cytotoxic T cells, whereas drug-resistant tumors adopted an immunosuppressive microenvironment with elevated MHC II-low macrophages and increased tumor cell PD-L1 expression. Excitingly, CDK4/6-MEK inhibition sensitized MPNSTs to anti–PD-L1 immune checkpoint blockade (ICB) with some mice showing complete tumor regression. Conclusions: CDK4/6-MEK inhibition induces a novel plasma cell-associated immune response and extended antitumor activity in MPNSTs, which dramatically enhances anti–PD-L1 therapy. These preclinical findings provide strong rationale for clinical translation of CDK4/6-MEK-ICB targeted therapies in MPNST as they may yield sustained antitumor responses and improved patient outcomes.

24 November 2023 in Science Advances
Verified
Journal Article
Open access
JWJiawan Wang
Jiawan Wang
ACAna Calizo
Ana Calizo
LZLindy Zhang
Lindy Zhang
JPJames C. Pino
James C. Pino
YLYang Lyu
Yang Lyu
CPChristine A. Pratilas
Christine A. Pratilas
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas with limited treatment options, and new effective therapeutic strategies are desperately needed. We observe antiproliferative potency of genetic depletion of PTPN11 or pharmacological inhibition using the SHP2 inhibitor (SHP2i) TNO155. Our studies into the signaling response to SHP2i reveal that resistance to TNO155 is partially mediated by reduced RB function, and we therefore test the addition of a CDK4/6 inhibitor (CDK4/6i) to enhance RB activity and improve TNO155 efficacy. In combination, TNO155 attenuates the adaptive response to CDK4/6i, potentiates its antiproliferative effects, and converges on enhancement of RB activity, with greater suppression of cell cycle and inhibitor-of-apoptosis proteins, leading to deeper and more durable antitumor activity in in vitro and in vivo patient-derived models of MPNST, relative to either single agent. Overall, our study provides timely evidence to support the clinical advancement of this combination strategy in patients with MPNST and other tumors driven by loss of NF1.

25 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LZLindy Zhang
Lindy Zhang
AMAlexandre Maalouf
Alexandre Maalouf
SMStavriani C. Makri
Stavriani C. Makri
JBJineta Banerjee
Jineta Banerjee
ASAditya Suru
Aditya Suru
NLNicolas J Llosa
Nicolas J Llosa
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas and the leading cause of mortality in individuals with neurofibromatosis type 1 (NF1). Despite many clinical trials, outcomes for patients with MPNST have remained stagnant, and most succumb to their disease; thus, novel therapeutic approaches are needed. A better understanding of the MPNST immune ecosystem will aid in the development of strategies to activate the immune system against the tumor. In this study, we profile the tumor immune microenvironment (TIME) in NF1-associated peripheral nerve sheath tumors (PNST) to discover insights on the role played by tumor-infiltrating immune cells in malignant transformation. Experimental Design: Using fresh and formalin-fixed paraffin-embedded tissue from patients diagnosed with NF1-PNST, we dissected the TIME through IHC, multiparameter flow cytometry, and comparative transcriptomic studies. Results: Immunophenotyping confirmed increased immune cell infiltration during malignant progression, with a predominance of infiltrating myeloid cells, particularly CD163+ tumor-associated macrophages (TAM). The T cells within MPNST exhibited signs of tumor activation, characterized by high programmed cell death 1 expression. Additionally, MPNST specimens demonstrated elevated levels of immunosuppressive TAM, with heightened PD-L1 expression. The proportion of CD163+ myeloid cells within the TIME correlated with poorer progression-free survival. Notably, loss of H3K27 trimethylation correlated with low immune cell infiltration in MPNST. Conclusions: Malignant transformation of NF1-PNST is characterized by an immunosuppressive microenvironment comprising TAM with high expression of PD-L1, which is associated with inferior outcomes. These findings suggest the clinical potential of immune-modulating therapeutics that can unleash an antitumor immune response.

1 January 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
LZLindy Zhang
Lindy Zhang
KLKathryn Lemberg
Kathryn Lemberg
ACAna Calizo
Ana Calizo
RVRavi Varadhan
Ravi Varadhan
ASAlan H Siegel
Alan H Siegel
CPChristine A. Pratilas
Christine A. Pratilas
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas originating from cellular components within the nerve sheath. The incidence of MPNST is highest in people with neurofibromatosis type 1 (NF1), and MPNST is the leading cause of death for these individuals. Complete surgical resection is the only curative therapeutic option, but is often unfeasible due to tumor location, size, or presence of metastases. Evidence-based choices of chemotherapy for recurrent/refractory MPNST remain elusive. To address this gap, we conducted a retrospective analysis of our institutional experience in treating patients with relapsed MPNST in order to describe patient outcomes related to salvage regimens. We conducted a retrospective electronic health record analysis of patients with MPNST who were treated at Johns Hopkins Hospital from January 2010 to June 2021. We calculated time to progression (TTP) based on salvage chemotherapy regimens. Sixty-five patients were included in the analysis. Upfront therapy included single or combined modalities of surgery, chemotherapy, or radiotherapy. Forty-eight patients received at least 1 line of chemotherapy, which included 23 different regimens (excluding active clinical studies). Most patients (n = 42, 87.5%) received a combination of doxorubicin, ifosfamide, or etoposide as first-line chemotherapy. Salvage chemotherapy regimens and their TTP varied greatly, with irinotecan/temozolomide-based regimens having the longest average TTP (255.5 days, among 4 patients). Patients with advanced or metastatic MPNST often succumb to their disease despite multiple lines of therapy. These data may be used as comparative information in decision-making for future patients and clinical trials.

26 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJineta Banerjee
Jineta Banerjee
YLYang Lyu
Yang Lyu
SMStavriani C. Makri
Stavriani C. Makri
ASAlexandra Jane Scott
Alexandra Jane Scott
LZLindy Zhang
Lindy Zhang
CPChristine A. Pratilas
Christine A. Pratilas
Background Neurofibromatosis type 1 (NF1) is a prevalent inherited neurocutaneous condition that predisposes to the development of peripheral nerve sheath tumors (PNST) including cutaneous neurofibromas (CNF), plexiform neurofibromas (PNF), atypical neurofibromatous neoplasms with unknown biological potential (ANNUBP), and malignant peripheral nerve sheath tumors (MPNST). Historically, therapeutic progress for PNF and MPNST has been limited in part due to restricted availability of primary tissues from patients with NF1. The successful advancement of therapeutic development for NF1-associated PNST necessitates ongoing efforts in the systematic acquisition and analysis of human tumor specimens and their corresponding model systems. Methods Patients with clinically or genetically confirmed NF1 having a clinically indicated surgical resection or biopsy of any NF1-associated tumor were invited to participate in an institutional review board (IRB) approved study for the collection and sharing of tissues and specimens. Tumors were assessed by the study pathologist, and banked in the laboratory as flash frozen tissues, paraffin embedded blocks or slides, DNA and RNA, or single cell suspensions. Efforts were made to create cell lines and patient derived xenografts (PDX) from primary human tissues. Clinical data for participating patients were fully annotated in a database that corresponds to banked tissue specimens. Applications for access to biospecimens, genomic data, and disease models, as well as de-identified clinical and molecular data are reviewed and approved with IRB oversight, to allow internal and external sharing to promote research collaboration. Results Since the inception of the JH NF1 biospecimen repository in 2016, 357 unique samples have been banked (from 183 unique patients) and include PNF (n=89), ANNUBP (n=6), MPNST (n=62), CNF (n=103), and diffuse neurofibroma (diffuse NF, n=44). Xenografts have successfully been generated from seven MPNST samples and cell lines have been generated from three PNF and seven MPNST. RNA sequencing (RNAseq) and whole genome sequencing (WES) data were generated from 73 and 114 primary human tumor samples, respectively. These pre-processed data, standardized for immediate computational analysis, are accessible through the NF Data Portal, allowing immediate interrogation. Our analysis herein highlights key genetic variants and alterations in gene expression patterns, linked to pathways implicated in the pathology of the NF1-associated tumor types represented in the dataset. This work also combines new sample data with previously released samples, offering a comprehensive view of the entire cohort sequenced to date. Somatic variants in genes including NF1, SUZ12 and LRP1 and LRP2 were identified in MPNST. Enrichment of RAS-RTK signaling pathways was identified through analysis of variants in both PNF and MPNST, however, MPNST demonstrated unique enrichment in pathways associated with extracellular matrix organization and cell cycle regulation. Conclusion Analysis of primary human tissue samples is critical for identification of therapeutically relevant molecular alterations. As a dedicated effort to systematically bank tumor samples from people with NF1 undergoing surgery, in collaboration with molecular geneticists and computational biologists who seek to advance understanding of NF1 biology, the Johns Hopkins NF1 biospecimen repository offers access to samples and genomic data to the NF1 research community to promote advancement of NF1-related therapies.

25 November 2025
Verified
Other
Open access
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Supplementary Figure S2. Dual CDK4/6-MEK inhibition synergistically suppresses the growth of some, but not all, MPNST PDXs in immune deficient mice